Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shana N. Thomas"'
Autor:
Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Publikováno v:
Cancer Research. 83:PD13-09
Background: CDK4/6 inhibitors (CDK4/6i) paired with endocrine therapy (ET) are considered first-line (1L) therapy for patients (pts) with HR+ HER2- advanced breast cancer (aBC). A minority of pts will demonstrate primary resistance to CDK4/6i, as cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc74005a8ddece22f16b5410d530c3b0
https://doi.org/10.1158/1538-7445.sabcs22-pd13-09
https://doi.org/10.1158/1538-7445.sabcs22-pd13-09
Publikováno v:
Cancer Research. 83:P2-23
Background: HER2 activating mutations occur in 2-5% of metastatic breast cancer (MBC) patients. These mutations cluster in the kinase domains and at amino acids 309-310 in the extracellular domain. The MutHER, SUMMIT, and PlasmaMATCH clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b46ed76713f005a9252a12964ace5f38
https://doi.org/10.1158/1538-7445.sabcs22-p2-23-10
https://doi.org/10.1158/1538-7445.sabcs22-p2-23-10